Manfred Windisch is VP R&D of NeuroScios, Graz, Austria, the company he founded in 2013. NeuroScios specializes in consulting for drug development programs in neurological indications and provides research services for clinical trials in dementia (AD, MCI, and others). Through NeuroScios, he makes his extensive previous experience more available to drug development companies, because without a direct affiliation to any preclinical contract research organizations (CROs), he can provide unbiased consultation. In 1999, he founded the CRO, JSW-Lifesciences, whose research activities were concentrated on the role of alpha- and beta-synuclein in the pathogenesis of PD and AD. He created and standardized transgenic and induced rodent models of neurodegenerative diseases and used these models in approximately 60–80 pharmacological studies each year, allowing him to define experimental standards to increase their predictive value. He was also involved in clinical studies in AD, MCI, PD, ALS, and cerebrovascular diseases, running about 32 international trials from Phase 1 to 3. This experience also included complex study design using state-of-the-art imaging techniques and CSF biomarkers. Since 2007 he is one of the executive organizers of the AD-PD conference.